Inventiva (NASDAQ:IVA) Sees Unusually-High Trading Volume – Still a Buy?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw an uptick in trading volume on Friday. Approximately 890,467 shares were traded during trading, an increase of 19% from the previous session’s volume of 751,098 shares. The stock last traded at $3.2550 and had previously closed at $3.26.

Analysts Set New Price Targets

Several equities analysts have issued reports on IVA shares. Guggenheim raised their price objective on Inventiva from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, September 15th. Cantor Fitzgerald started coverage on Inventiva in a report on Friday, July 17th. They issued an “overweight” rating for the company. Piper Sandler restated an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $15.75.

Inventiva Stock Performance

The company’s 50-day simple moving average is $4.45 and its 200-day simple moving average is $4.77.

Hedge Funds Weigh In On Inventiva

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Engineers Gate Manager LP increased its position in Inventiva by 155.5% in the 2nd quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the period. Seven Fleet Capital Management LP acquired a new position in shares of Inventiva in the first quarter valued at approximately $1,111,000. Persistent Asset Partners Ltd purchased a new stake in shares of Inventiva during the fourth quarter worth approximately $603,000. NEXTBio Capital Management LP acquired a new stake in shares of Inventiva during the fourth quarter worth $6,039,000. Finally, Eventide Asset Management LLC acquired a new stake in shares of Inventiva during the fourth quarter worth $1,155,000. Hedge funds and other institutional investors own 19.06% of the company’s stock.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.